US 2013 01 08693A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0108693 A1 VERGEZ. et al. (43) Pub. Date: May 2, 2013 (54) DUAL CONTROLLED RELEASE DOSAGE Publication Classification FORM (51) Int. Cl. (71) Applicants: Juan A. VERGEZ, Buenos Aires (AR): A619/00 (2006.01) Marcelo A. RICCI, Buenos Aires (AR) A619/24 (2006.01) 469/48 (2006.01) (72) Inventors: Juan A. VERGEZ, Buenos Aires (AR): A6II 45/06 (2006.01) Marcelo A. RICCI, Buenos Aires (AR) (52) U.S. Cl. CPC ............... A61 K9/0004 (2013.01); A61K 45/06 (2013.01); A61 K9/209 (2013.01); A61 K SZOLGALTATO KFT, Budapest (HU) USPC ........... 424/452: 424/400: 514/646; 514/423; 514/342: 514/226.2: 514/534; 514/220; (21) Appl. No.: 13/625,658 514/422; 424/465 (57) ABSTRACT (22) Filed: Sep. 24, 2012 A dosage form that provides a controlled release of at least two different active agents is provided. Particular embodi O O ments include a dosage form that provides therapeutically Related U.S. Application Data effective levels of a first active agent and a second active agent (60) Continuation of application No. 1 1/355,315, filed on in a mammal for an extended period of time following oral Feb. 15, 2006, now Pat. No. 8,329,217, which is a administration. An osmotic device containing a bi-layered continuation-in-part of application No. 1 1/321,736, core is provided. The osmotic device provides a dual con filed on Dec. 29, 2005, now Pat. No. 8,241,667, which trolled release of both drugs from the core. The layers of the is a division of application No. 09/992.488, filed on core are in Stacked, Substantially concentric or Substantially Nov. 6, 2001, now abandoned. eccentric arrangement. Patent Application Publication May 2, 2013 Sheet 1 of 3 US 2013/01 08693 A1 Patent Application Publication May 2, 2013 Sheet 2 of 3 US 2013/01 08693 A1 FIG. 6 Figure 6. Dissolution profile of example 1 8 1O 12 14 16 18 2O 22 24 Time (hrs)-O-Oxybutynin -O-Tolterodine FIG. 7 OO 8 10 12 14 16 18 20 22 24 Time (hrs) -O-Oxybutynin -O-Darifenacin Patent Application Publication May 2, 2013 Sheet 3 of 3 US 2013/01 08693 A1 FIG. 8 1OO - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - O 2 4 6 8 O 12 14 16 18 2O 22 24 Time (hrs) -O-Oxybutynin-O-Darifenacin 60 FIG 11 62 US 2013/01 08693 A1 May 2, 2013 DUAL CONTROLLED RELEASE DOSAGE 0007 U.S. Pat. No. 5,543,155 to Fekete et al. discloses an FORM osmotic device comprising a bi-layered core Surrounded by a semipermeable membrane having two holes (or passage CROSS-REFERENCE TO EARLIER FILED ways). The bi-layered core, however, comprises a first push APPLICATIONS layer containing no drug and a second layer containing drug. The hole(s) can be placed anywhere along the semipermeable 0001. This application claims the benefit of and is continu membrane. This patent does not disclose a core having two ation of U.S. Ser. No. 1 1/355,315, filed Feb. 15, 2006, which different drug-containing layers, each providing a controlled is a continuation-in-part of U.S. application Ser. No. 1 1/321, release of drug through a respective hole in the semiperme 736 filed Dec. 29, 2005, which is a divisional of U.S. appli able membrane. cation Ser. No. 09/992,488 filed Nov. 6, 2001, now aban doned, the entire disclosures of which are hereby 0008 U.S. Pat. No. 4,662.880 to Hamel et al., U.S. Pat. incorporated by reference. No. 4,723,957, U.S. Pat. No. 4,867,969 and U.S. Pat. No. 4,971,790 to Magruder et al. disclose osmotic devices com FIELD OF THE INVENTION prising a single-layered core Surrounded by a semipermeable membrane having two oppositely placed holes. A drug-con 0002 This invention pertains to a dosage form that pro taining coat further Surrounds the semipermeable membrane. vides a controlled release of two different drugs. More par These patents do not disclose a core having two different ticularly, it pertains to a coated dosage form having a bilay drug-containing layers, each providing a controlled release of ered core wherein each layer includes a respective drug that is drug through a respective hole in the semipermeable mem released in a controlled manner. brane. BACKGROUND OF THE INVENTION 0009 U.S. Pat. No. 4,624,847 to Ayer et al. discloses an osmotic device comprising a semipermeable membrane Sur 0003. Osmotic devices and other tablet formulations are rounding a compartment that houses a drug-containing poly known for their ability to provide a controlled release of a mer that increases in size and releases drug. The semiperme wide range of drugs. Such osmotic devices and other tablet able membrane has two oppositely placed holes for releasing formulations are disclosed in U.S. Pat. No. 4,014,334 to drug. This patent does not disclose an osmotic device com Theeuwes et al., U.S. Pat. No. 4,576,604 to Guittard et al., prising core having two different drug-containing layers, Argentina Patent No. 234,493, U.S. Pat. No. 4,673.405 to each providing a controlled release of drug through a respec Guittard et al., U.S. Pat. No. 5,558,879 to Chenet al., U.S. Pat. tive hole in the semipermeable membrane. No. 4,810,502 to Ayeret al., U.S. Pat. No. 4,801.461 to Hamel (0010 U.S. Pat. No. 4,915,954 to Ayer et al. and U.S. Pat. et al., U.S. Pat. No. 5,681,584 to Savastano et al., U.S. Pat. No. No. 4,814,181 to Jordan et al. disclose an osmotic device 3,845,770 and Argentina Patent No. 199,301, the entire dis having a bi-layered core Surrounded by a semipermeable closures of which are hereby incorporated by reference. membrane. The first layer comprises a first drug that is 0004 Osmotic devices have demonstrated utility in deliv released from the core rapidly over a period of 2 minto 2 hr. ering beneficial active agents, such as medicines, nutrients, The second layer comprises a second drug that is released food, pesticides, herbicides, germicides, algaecides, chemi from the core at a controlled rate over a long period of time. cal reagents, and others, to an environment of use in a con The layers of the core are in intimate contact and are not trolled manner over prolonged periods of time. Known separated by another layer, lamina or membrane. The semi devices include tablets, pills, and capsules. permeable membrane can have two holes, one hole adjacent 0005 Advancements in the art have focused on develop each of the two layers of the core such that each layer releases ing osmotic devices with improved semipermeable or porous drug through its own respective hole. The Ayer et al. and membranes, various coatings Surrounding the core and/or the Jordan et al. patents do not disclose an osmotic device having semipermeable membrane, layered osmotically effective a bi-layered core, wherein the layers are in contact with each agents in the core of the device, specific release profiles for other and in laminar arrangement with respect to one another specific active Substances, and specific membrane or core and wherein each layer provides a prolonged and controlled compositions. release of an active agent. 0006 U.S. Pat. No. 4,931,285, U.S. Pat. No. 5,006,346 and U.S. Pat. No. 5,160,743 to Edgren et al., U.S. Pat. No. 0011 U.S. Pat. No. 4,455,143 to Theeuwes et al. discloses 5,160,744, U.S. Pat. No. 5,190,765 and U.S. Pat. No. 5,252, an osmotic device having two compartments defined by a 338 to Jao et al., U.S. Pat. No. 4,612,008, U.S. Pat. No. Surrounding semipermeable membrane and a partition 4,765,989 and U.S. Pat. No. 5,082,668 to Wong et al., U.S. between the compartments. The semipermeable membrane Pat. No. 4,327,725 to Cortese et al., U.S. Pat. No. 5,208,037 has two oppositely placed holes, one for each compartment. to Wright et al., U.S. Pat. No. 4,904,474 to Theeuwes et al. Each compartment contains a drug that is delivered at a con and U.S. Pat. No. 4,627,971 to Ayer disclose osmotic devices trolled rate through a respective hole in the Surrounding mem comprising a bi-layered core Surrounded by a semipermeable brane. The partition is required and retains its integrity during membrane having at least one hole (or passageway). The operation of the osmotic device. bi-layered core, however, comprises a first push-layer con (0012 U.S. Pat. No. 5,866,164 to Kuczynski et al. of Alza taining no drug and a second layer containing drug. The Corporation discloses an osmotic device having a bi-layered hole(s) can be placed anywhere along the semipermeable core Surrounded by a semipermeable membrane. There is no membrane. These patents do not disclose a core having two partition between the layers. The core includes a drug-con different drug-containing layers, each providing a controlled taining layer and a push-layer; and passageways in the Sur release of drug through a respective hole in the semiperme rounding semipermeable membrane only communicate the able membrane. drug-containing layer, and not the push-layer, to the exterior US 2013/01 08693 A1 May 2, 2013 of the device.